MedImmune signs two RSV deals

MEDI received an exclusive worldwide license to use MEDX's HuMAb-mouse technology to develop antibodies against respiratory syncytial virus (RSV) and an option to license the technology for additional antigens. MEDX received technology access fees and could receive license fees and milestones plus royalties. ...